⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Psilocybin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-17 — Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life: LONG-LIFE Phase I trial (protocol-stage, no efficacy readout) will test 1–3 doses of 25 mg psilocybin vs. wait-list in medically stable adults 60–80, with endpoints spanning aging biomarkers, cognition, and purpose/meaning in life. [human-rct] (novelty: 4)
- 2026-08-07 — Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin: Early-stage clinical trial (protocol-stage, no efficacy readout) testing intermittent oral psilocybin (two doses 2 weeks apart) as an adjunct to cognitive training vs. cognitive training alone in adults 65+ with MCI, early Alzheimer’s, or normal cognition, targeting neuroplasticity and brain function endpoints. [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life
17-aug-2026
novelty 4
per-area 4
strengthens
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
07-aug-2026
novelty 3
per-area 3
strengthens